COGNITION THERAPEUTICS Files 8-K on Financial Results

Ticker: CGTX · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001455365

Cognition Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyCognition Therapeutics INC (CGTX)
Form Type8-K
Filed DateMar 26, 2026
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: earnings, financial-results, regulation-fd, 8-k

TL;DR

**COGNITION THERAPEUTICS just dropped an 8-K with fresh financial results, so expect market reaction.**

AI Summary

COGNITION THERAPEUTICS INC filed an 8-K on March 26, 2026, disclosing results of operations and financial condition under Item 2.02 and Regulation FD Disclosure under Item 7.01. This filing includes Exhibits 99.1 and 99.2, which are likely press releases or investor presentations containing financial updates. For investors, this matters because it provides the latest financial performance data, which can influence stock price and future investment decisions.

Why It Matters

This filing provides investors with the most recent financial performance and operational updates, which are crucial for evaluating the company's health and future prospects.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the undisclosed financial results within Exhibits 99.1 and 99.2 could contain positive or negative news, introducing market risk.

Analyst Insight

A smart investor would review Exhibits 99.1 and 99.2 immediately to understand the detailed financial results and operational updates before making any investment decisions.

Key Players & Entities

Forward-Looking Statements

FAQ

What specific items were reported in this 8-K filing by COGNITION THERAPEUTICS INC?

COGNITION THERAPEUTICS INC reported under Item 2.02: Results of Operations and Financial Condition, and Item 7.01: Regulation FD Disclosure, on March 26, 2026.

What are the accession number and filing date for this 8-K?

The SEC Accession No. is 0001104659-26-034876, and the filing date is March 26, 2026.

What exhibits were included with this 8-K filing?

This 8-K filing included EXHIBIT 99.1 (tm269805d1_ex99-1.htm) and EXHIBIT 99.2 (tm269805d1_ex99-2.htm), along with several graphic files.

What is the purpose of Item 2.02 in an 8-K filing?

Item 2.02 of an 8-K filing is used to disclose material non-public information regarding a company's results of operations and financial condition, typically through an earnings release.

How many documents were included in this specific 8-K submission?

The filing detail indicates there were 45 documents, including the FORM 8-K, exhibits, and numerous graphic files, with a complete submission text file and several XBRL data files.

Filing Stats: 637 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2026-03-26 07:36:48

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 26, 2026, Cognition Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information disclosed under Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation that the Company may use from time to time in presentations or discussions with investors, analysts, and other parties. The information in this Item 7.01 (including Exhibit 99.2) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Press Release, dated March 26, 2026. 99.2 Investor presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. Date: March 26, 2026 By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing